Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Graft-Versus-Host Disease: early-phase trial registry
12 of 42 indexed Graft-Versus-Host Disease trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #347 of 28,707 conditions by registered trial count.
42 US clinical trials · 12 currently recruiting · #347 of 28,707 conditions by registered trial count
Graft-Versus-Host Disease: 42 US clinical trials tracked, 12 recruiting.
Graft-Versus-Host Disease is the subject of 42 registered US clinical trials on ClinicalTrials.gov, 12 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 33 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition graft-versus-host-disease
OPEN 12 | RECR 29% | LATE 2 | EARLY 33 | RANK #347 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Acne Scars (29% recruiting · 7 trials)
Graft-Versus-Host Disease lists 12 open slots (29% of 42 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Graft-Versus-Host Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Graft-Versus-Host Disease is recruiting below its size-band peers.
12 of 42 indexed trials (28.6%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Graft-Versus-Host Disease trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 5 of 42 trials (11.9%). 32 distinct sponsors appear on at least one study for this condition label.
-
Most Graft-Versus-Host Disease trials plan to enrol fewer than 100 people.
Median target enrolment is 38 among the 39 trials that report a genuine target (sentinel values excluded). 34 of those (87.2%) plan for fewer than 100 participants.
-
Graft-Versus-Host Disease research is mostly interventional.
37 interventional and 5 observational studies make up this index (88.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
42 total, page 1 of 1
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
National Heart, Lung, and Blood Institute (NHLBI)
NCT00001529
Chronic Graft-versus-Host Disease in the Oral Cavity of Patients Following Allogeneic Hematopoietic Stem Cell Transplant and Including Healthy Controls
National Institute of Dental and Craniofacial Research (NIDCR)
NCT03602599
Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients
University of Michigan Rogel Cancer Center
NCT05866302
Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease
Massachusetts General Hospital
NCT06910969
A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant
Christopher Dvorak
NCT04337515
A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT07006506
A Study of Photobiomodulation (PBM) Therapy in People With Oral Graft-Versus-Host Disease (GVHD) After Stem Cell Transplant
Memorial Sloan Kettering Cancer Center
NCT05675930
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Jonathan Brammer
NCT07356245
Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT06008808
Dose-Escalation Trial of Mesenchymal Stromal Cells in Patients With Medical Xerostomia
University of Wisconsin, Madison
NCT06392711
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
City of Hope Medical Center
NCT06815003
PTCY Plus uhCG/EGF for Graft Versus Host Disease Prophylaxis
Henry Ford Health System
NCT04886726
Optimizing PTCy Dose and Timing
National Cancer Institute (NCI)
NCT03983850
Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)
Northwell Health
NCT05289167
De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis
Medical College of Wisconsin
NCT05622318
Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
Roswell Park Cancer Institute
NCT03192397
Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant
Emory University
NCT03924401
Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases
Roswell Park Cancer Institute
NCT00003662
Topical Fibrinogen-Depleted Human Platelet Lysate in Patients With Dry Eye Secondary to Graft vs. Host Disease
Cambium Bio Limited
NCT03414645
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
University of Michigan Rogel Cancer Center
NCT02145403
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
NCT00410657
RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation
Regimmune Corporation
NCT04014790
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
University of Maryland, Baltimore
NCT00003398
Pentostatin in Treating Patients With Refractory Chronic Graft-Versus-Host Disease
Alliance for Clinical Trials in Oncology
NCT00074035
Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease
H. Lee Moffitt Cancer Center and Research Institute
NCT01795573
Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT
University of Florida
NCT02398708
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Memorial Sloan Kettering Cancer Center
NCT00423514
Campath-1H + FK506 and Methylprednisolone for GVHD
Case Comprehensive Cancer Center
NCT00109993
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT02342613
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
City of Hope Medical Center
NCT00589563
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
Dana-Farber Cancer Institute
NCT00144677
A Proof of Concept Pilot Trial of Alpha-1-Antitrypsin for Pre-Emption Of Steroid-Refractory Acute GVHD
John Levine
NCT03459040
Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation
Washington University School of Medicine
NCT04131738
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
Monica Bhatia
NCT02867800
Allogeneic Transplantation From Related Haploidentical Donors
Stanford University
NCT00185692
Feasibility Study of Collecting Multicenter Chronic GVHD Data
M.D. Anderson Cancer Center
NCT00506233
Study of MEDI 507 in the Treatment of Pediatric Patients
MedImmune
NCT00813618
Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy
Dana-Farber Cancer Institute
NCT00005988
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
Roswell Park Cancer Institute
NCT00003661
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
Memorial Sloan Kettering Cancer Center
NCT00014469
Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease
Memorial Sloan Kettering Cancer Center
NCT00043147
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
NCT00004232
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 16 |
| Phase 2 | 17 |
| Phase 3 | 1 |
| Phase 4 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Graft-Versus-Host Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Graft-Versus-Host Disease trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Graft-Versus-Host Disease page
42 registered trials, 12 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 12 Graft-Versus-Host Disease trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Graft-Versus-Host Disease trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Graft-Versus-Host Disease condition card totals 42 registered trials; most-linked intervention methylprednisolone; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.